$TRIL $ALXO -- Trillium Patent Vindicated; Nonobvious, and Unexpectedly Superior -- A PTI Thread

$TRIL $ALXO -- Trillium Patent Vindicated; Nonobvious, and Unexpectedly Superior -- A PTI Thread

Trillium, in usual understated style, relays the good news of its patent victory in its latest corporate deck.

I juxtapose that news against the now famous CD47 comparo slide:
-

$TRIL $ALXO -- Trillium Patent Vindicated; Nonobvious, and Unexpectedly Superior -- A PTI Thread -- 2 of 14

Let's keep things in perspective -- no one's going to court just yet (or ever) --

But an incremental positive for $TRIL's differentiated science:
. . .

$TRIL $ALXO -- Trillium Patent Vindicated; Nonobvious, and Unexpectedly Superior -- A PTI Thread -- 3 of 14

$TRIL's intellectual claim -- it's about fusion, and method of use -- and the implications are interesting:
. . .

$TRIL $ALXO -- Trillium Patent Vindicated; Nonobvious, and Unexpectedly Superior -- A PTI Thread -- 4 of 14

Take note that, as $TRIL points out, the method of use covers both heme malignancies and solid tumors:
. . .

$TRIL $ALXO -- Trillium Patent Vindicated; Nonobvious, and Unexpectedly Superior -- A PTI Thread -- 5 of 14

And, here's the meat of the claim -- the method of use, and for what purpose:
. . .

$TRIL $ALXO -- Trillium Patent Vindicated; Nonobvious, and Unexpectedly Superior -- A PTI Thread -- 6 of 14

So, what's it all mean? What are the potential practical applications?

Well, it's both Narrow, and Broad:
. . .

$TRIL $ALXO -- Trillium Patent Vindicated; Nonobvious, and Unexpectedly Superior -- A PTI Thread -- 7 of 14

Narrow, yes -- but what about Shattuck Labs ( $STTK ) ?
. . .

$TRIL $ALXO -- Trillium Patent Vindicated; Nonobvious, and Unexpectedly Superior -- A PTI Thread -- 8 of 14

IP law is murky at best of times, but still, USPTO's reversal, in favor of $TRIL is promising in particular because of its rationale for reversal (more, later):
.

$TRIL $ALXO -- Trillium Patent Vindicated; Nonobvious, and Unexpectedly Superior -- A PTI Thread -- 9 of 14

Initially, $TRIL's claim was all to obvious to the USPTO -- in other words, not patentable...
. . .

$TRIL $ALXO -- Trillium Patent Vindicated; Nonobvious, and Unexpectedly Superior -- A PTI Thread -- 10 of 14

But, the $TRIL patent tide turns with an unexpected result -- and a $TRIL slide illustrates that result, well:
. . .

$TRIL $ALXO -- Trillium Patent Vindicated; Nonobvious, and Unexpectedly Superior -- A PTI Thread -- 11 of 14

Unrebutted evidence of $TRIL 621 & 622 differentiation with respect to RBC binding and agglutination--

good for patent, great for patient:
. . .

$TRIL $ALXO -- Trillium Patent Vindicated; Nonobvious, and Unexpectedly Superior -- A PTI Thread -- 12 of 14

The Patent Battle's Won, but so what?

One small step, but it could be a giant leap in a giant's hands:
. . .

$TRIL $ALXO -- Trillium Patent Vindicated; Nonobvious, and Unexpectedly Superior -- A PTI Thread -- 13 of 14

It'll probably never reach court, but if it does -- USPTO's rationale for reversal is a strength to $TRIL patent

Presupposed obviousness, already overcome:
. .

$TRIL $ALXO -- Trillium Patent Vindicated; Nonobvious, and Unexpectedly Superior -- A PTI Thread -- 14 of 14

I wonder who likes strong IP positions?

As always, bring the data -- but the IP? Well, that story is already being written:
. . .

$TRIL $ALXO -- Trillium Patent Vindicated; Nonobvious, and Unexpectedly Superior -- Addendum to come?

ALX148 is all too human...